Heart Failure Seminar - Dr. Pablo Álvarez Rocha

Definition and Significance of Heart Failure
📌 Heart failure (HF) is a clinical syndrome characterized by symptoms and signs resulting from a structural or functional cardiac anomaly leading to a reduction in cardiac output or maintenance of cardiac output at the expense of elevated filling pressures.
📈 The prevalence of HF is closely linked to age, reaching up to 20% in individuals over 80 years old.
🏥 HF incurs significant healthcare costs, primarily due to expenses related to hospitalization and readmissions.

Pathophysiology and Compensatory Mechanisms
💔 Myocardial dysfunction, stemming from conditions like ischemic heart disease, cardiomyopathies, or hypertension, results in two main phenotypes: a thickened, less compliant heart causing diastolic dysfunction, or a dilated, hypertrophied heart causing systolic dysfunction.
📉 Ventricular dysfunction causes a decrease in cardiac output and a subsequent drop in mean arterial pressure, leading to hypoperfusion.
🔄 The body compensates via the neurohormonal model, involving the sympathetic nervous system (increased contractility, vasoconstriction) and the renin-angiotensin system (salt/water retention, vasoconstriction), which ultimately contribute to a vicious cycle of progression via mechanical toxicity and fibrosis.

Hemodynamic Consequences and Therapeutic Targets
🌬️ Retrograde effects of ventricular dysfunction lead to increased left ventricular end-diastolic pressure, resulting in pulmonary congestion and increased systemic venous pressure.
💊 Therapeutic benefits are derived from targeting these compensatory mechanisms: beta-blockers counteract sympathetic toxicity, ACE inhibitors mitigate oxidative stress and remodeling from the renin-angiotensin system, and aldosterone antagonists are beneficial, particularly in HF with reduced ejection fraction (HFrEF).
💧 Diuretics provide fundamental symptomatic and hemodynamic management by addressing fluid overload caused by hydro-saline retention due to renal hypoperfusion.

Diagnostic Pillars of Heart Failure
🔬 Diagnosis relies on clinical evaluation, electrocardiogram (ECG), chest X-ray (CXR), echocardiogram, and biomarkers.
🔗 An ECG is essential, though abnormality is expected; a completely normal ECG should prompt questioning of the HF diagnosis.
🖼️ CXR provides anatomical information (cardiothoracic index < 0.5 is normal) and hemodynamic assessment (signs of venous hypertension like redistribution of flow to lung apices, Kerley lines 'A' and 'B', and alveolar edema visualized via air bronchograms).

Echocardiography and Biomarkers in Diagnosis
❤️ The echocardiogram is highly valuable; it is unlikely to diagnose HF if no structural or functional abnormality is detected.
📊 Systolic function is assessed using the left ventricular ejection fraction (LVEF), calculated as the percentage of end-diastolic volume expelled (normal: 50-70%).
🔹 HF is classified based on LVEF: HFrEF (LVEF < 40%), HFpEF (LVEF $\ge$ 50%), and an intermediate range (40-49%).
💖 B-type natriuretic peptide (BNP) and its precursor (proBNP) are key biomarkers; their secretion correlates strongly with myocardial stress (high diastolic pressure/wall stress). A normal BNP result offers a high negative predictive value, making HF unlikely in untreated patients.

Key Points & Insights
➡️ Heart failure is a syndrome defined by symptoms due to structural/functional anomalies causing reduced cardiac output or elevated filling pressures.
➡️ Beta-blockers and ACE inhibitors provide morbidity/mortality benefits by blocking detrimental, sustained neurohormonal activation.
➡️ LVEF dictates therapeutic evidence: Strong drug efficacy data exists for HFrEF (LVEF < 40%); evidence for HFpEF (LVEF $\ge$ 50%) is less certain.
➡️ A normal BNP value, in an untreated patient, suggests it is unlikely that the patient has heart failure, as these markers reflect myocardial stress.

📸 Video summarized with SummaryTube.com on Mar 18, 2026, 15:14 UTC